IMNN logo

IMUNON INC

IMNNNASDAQ
๐Ÿ† #5040 by market capEarnings Mar 29 ยท PostUS Equity
$0.54โ–ผ $0.03 (โˆ’5.22%)
Market closed ยท at close
๐Ÿ””
Track IMNN
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ผ 5.2%
7dโ–ผ 16.9%
14dโ–ผ 35.5%
30dโ–ผ 55.7%
ytdโ–ผ 85.0%
1yโ–ผ 85.6%
๐ŸฆMarket Cap
$3M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
0.0%
Slowing
๐Ÿ“ŠGross Margin
0.0%
Thin
๐Ÿ’ตFCF Margin
0.0%
Thin
โš–๏ธP/S Ratio
0.0x
Cheap
Otter Score
โ€”
Insufficient data

Trading Snapshot

Day Range
$0.53 โ€“ $0.58
52-Week Range
$0.50 โ€“ $4.35
Volume (shares)
49,701
Avg Volume (shares)
โ€”
Shares Outstanding
6.5M
Next Earnings
2027-03-29

Fundamentals Snapshot

Annual Revenue
โ€”
Last Q Revenue
โ€”
P/E Ratio
-0.1
P/S Ratio
0.0x
EPS (TTM)
$-2.53
Dividend Yield
0.00%
Dilution (1yr)
+91.0%
IMNN logo

IMUNON INC

IMNN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%โ–ฒ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnโ€™t profitable yet.
โˆ’$15Mโ–ผ โˆ’23.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
โˆ’$14Mโ–ผ โˆ’24.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerโ€™s slice.
2.1Mโ–ฒ +91.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$8Mโ–ฒ +$3M YoY
StockOtter ยท stockotter.space

About IMUNON INC

Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿ’งDilutionโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100

Analyst Ratings

โ“˜
Consensus
Buy
10 analysts
Strong Buy2
Buy7
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

Seeking Alphaยท10d ago

Imunon, Inc. (IMNN) Q3 2026 Earnings Call Transcript

Imunon, Inc. (IMNN) Q3 2026 Earnings Call Transcript

GlobeNewsWireยท10d ago

IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update

IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer

GlobeNewsWireยท16d ago

IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer

Analysis of paired patient biopsies from the randomized Phase 2 OVATION 2 study shows IMNN-001 increased CD8+/Treg, CD8+/CD4+ and CD8+/IDO+ ratios in both tumor and stroma

GlobeNewsWireยท20d ago

IMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026

LAWRENCEVILLE, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Company will host a conference

GlobeNewsWireยทOct 21

IMUNON Announces Strategic Sale of ThermoDoxยฎ

Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma Trial

GlobeNewsWireยทOct 8

IMUNON to Participate in Upcoming Investor Conferences

LAWRENCEVILLE, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that Stacy Lindborg, Ph.D.